Ardsley Advisory Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Ardsley Advisory Partners’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-650,000	Closed	-$4.01M	–	191
2019 Q2	$4.01M	Sell	650,000 -605,000	-48%	-$2.92M	0.63%	40
2019 Q1	$5.82M	Buy	1,255,000 +727,900	+138%	+$3.29M	1.12%	30
2018 Q4	$2.21M	Sell	527,100 -1,517,900	-74%	-$7.73M	0.56%	35
2018 Q3	$12.8M	Sell	2,045,000 -85,000	-4%	-$653K	1.73%	19
2018 Q2	$17.1M	Hold	2,130,000	–	–	2.58%	10
2018 Q1	$15.9M	Buy	2,130,000 +300,000	+16%	+$1.99M	2.38%	15
2017 Q4	$10.9M	Sell	1,830,000 -80,000	-4%	-$486K	1.32%	23
2017 Q3	$14.1M	Buy	1,910,000 +1,400,000	+275%	+$8.89M	1.87%	12
2017 Q2	$3.46M	Buy	510,000 +131,500	+35%	+$971K	0.54%	54
2017 Q1	$3.57M	Buy	378,500 +108,500	+40%	+$1.08M	0.56%	57
2016 Q4	$2.33M	Sell	270,000 -190,000	-41%	-$1.4M	0.39%	62
2016 Q3	$2.91M	Buy	460,000 +60,000	+15%	+$363K	0.46%	58
2016 Q2	$1.69M	Buy	+400,000	New	+$1.93M	0.29%	58

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Ardsley Advisory Partners's PGNX Position: Q3 2019 in Review

Ardsley Advisory Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2019, closing a stake of 650,000 shares — an estimated $4.01M sold.

Ardsley Advisory Partners first reported a position in PGNX in Q2 2016 and held it in 13 quarters. The position peaked at $17.1M in Q2 2018. 135 funds tracked by Wall St. Rank hold PGNX as of Q3 2019.

Ardsley Advisory Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2019 after selling out during the quarter.
Ardsley Advisory Partners sold 650,000 Progenics Pharmaceuticals Inc shares in Q3 2019, an estimated $4.01M.
Ardsley Advisory Partners first reported a position in Progenics Pharmaceuticals Inc in Q2 2016 and held it in 13 quarters.
Ardsley Advisory Partners's Progenics Pharmaceuticals Inc position peaked at $17.1M in Q2 2018.
135 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2019.

Based on Ardsley Advisory Partners's 13F filing for Q3 2019, filed 14 Nov 2019.